Britain and America have concluded a significant commercial pact that will preserve zero duties on UK drug shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This commitment secures that duties on these vital products will stay at nothing for a period of three years.
This agreement is in response to earlier threats to significantly raise duties on patented pharmaceutical products, with potential rates mentioned up to double the cost.
"This deal between the UK reinforces the worldwide climate for new treatments and establishes long-overdue balance to U.S.–U.K. drug exports," an announcement noted.
Trade Impact
Medicines represent one of the the United Kingdom's biggest exports to the America, which is easily the primary market for large British pharmaceutical firms.
Trade data show that in the 12 months leading up to September, the UK exported medicines worth £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards employment, boosts investment and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact involves several notable changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to double overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds were more than twenty percent.
Recent Tensions
This agreement follows a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were heightened by claims that American consumers were paying a premium for the equivalent treatments than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.